KK
CLDX icon

KLP Kapitalforvaltning’s Celldex Therapeutics CLDX Stock Holding History

KLP Kapitalforvaltning’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$566K Buy
15,200
+2,400
+19% +$77.5K ﹤0.01% 1459
2026
Q1 		$406K Hold
12,800
– – ﹤0.01% 1516
2025
Q4 		$348K Buy
12,800
+700
+6% +$18.4K ﹤0.01% 1591
2025
Q3 		$313K Hold
12,100
– – ﹤0.01% 1632
2025
Q2 		$246K Hold
12,100
– – ﹤0.01% 1685
2025
Q1 		$220K Hold
12,100
– – ﹤0.01% 1711
2024
Q4 		$306K Buy
+12,100
New +$329K ﹤0.01% 1636

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KLP Kapitalforvaltning's CLDX Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Celldex Therapeutics (CLDX) stake by 19% in Q2 2026, buying an estimated $77.5K and bringing the position to 15,200 shares worth $566K. The position accounts for ﹤0.01% of the portfolio, ranked #1459.

KLP Kapitalforvaltning first reported a position in CLDX in Q4 2024 and has held it in 7 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • KLP Kapitalforvaltning held 15,200 shares of Celldex Therapeutics worth $566K as of Q2 2026.
  • KLP Kapitalforvaltning bought 2,400 Celldex Therapeutics shares in Q2 2026, an estimated $77.5K.
  • Celldex Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1459 holding.
  • KLP Kapitalforvaltning first reported a position in Celldex Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.